Active	Status	Sponsor type	Region	Phase	Filter
4 Active 4 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dore, Greg
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir	Recruiting	4	30	RoW	Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret	Kirby Institute	Hepatitis C	02/26	02/26
CEASE, NCT02102451: Control and Elimination Within Australia of Hepatitis C From People Living With HIV	Active, not recruiting	N/A	492	RoW		Kirby Institute	Hepatitis C, HIV, HIV-HCV Coinfection	12/22	12/22
Montebello, Mark
NCT05042544: The National Australian HCV Point-of-Care Testing Program	Recruiting	N/A	40000	RoW	Point-of-Care Testing	Kirby Institute, Flinders University	Hepatitis C	12/24	12/26
ETHOS II, NCT03685045: ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings	Recruiting	N/A	6000	RoW	Campaign days	Kirby Institute, National Health and Medical Research Council, Australia	Hepatitis C	01/25	01/25